Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK109 and AK104 with chemotherapy in second-line gastric/GEJ adenocarcinoma
NCT04982276Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Aug 2021
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pulocimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Aug 2021; status: recruiting.
02
Drugs
pulocimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04982276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982276.